
https://www.science.org/content/blog-post/pains-go-mainstream
# Article Title (September 2014)

## 1. SUMMARY
This commentary discusses a Nature article by Jonathan Baell and Michael Walters about PAINS (Pan-Assay Interference Compounds) - problematic chemical compounds that produce false positive results in drug screening assays. These compounds appear to show biological activity through non-specific mechanisms rather than genuine drug-like binding to target proteins.

The article highlights how academic researchers, particularly those new to drug discovery, often mistake these artifacts for promising drug candidates without performing proper validation. Rhodanines serve as a key example - over 2,100 rhodanines were reported as biologically active across 410 papers from 290 organizations (mostly academic), yet none have progressed to clinical development despite some being patented. The commentary emphasizes rigorous validation steps: purity checks (LC/MS, NMR), aggregation testing with detergents, promiscuity screening across diverse assays, and ultimately resynthesis to confirm activity.

## 2. HISTORY
The PAINS concept, introduced by Baell and Holloway in 2010, gained significant traction after this 2014 commentary. The PAINS filters became widely adopted in academic and pharmaceutical screening programs. Major compound vendors began flagging PAINS structures, and scientific journals increasingly required PAINS screening for chemical biology publications.

Several rhodanine-containing compounds entered clinical trials between 2015-2020 but ultimately failed or were discontinued, including compounds for diabetes and cancer. No rhodanine-based drug received FDA approval. The pharmaceutical industry largely abandoned these scaffolds, while academic groups continued publishing rhodanine "hits" through the late 2010s.

The PAINS framework evolved into more sophisticated computational filters and expanded databases. By 2020, major drug discovery platforms routinely incorporated PAINS screening as standard practice, reducing false positives in early-stage screening campaigns. However, debates continued about whether PAINS filtering might eliminate potentially valuable compounds, leading to refinement rather than wholesale rejection of the concept.

## 3. PREDICTIONS
• **Prediction**: "We regard the effort to obtain and protect these patents [for rhodanines] as a waste of money" and "to our knowledge, no rhodanine plucked out of a screening campaign is in the clinic or even moving towards clinical development"

**Outcome**: Accurate. Despite 280+ patents filed for rhodanines, none advanced to FDA approval. Several rhodanine compounds entered clinical trials but failed. The financial investment in rhodanine patents proved largely unproductive.

• **Prediction**: PAINS compounds require excessive validation effort with uncertain outcomes - "you'd better assume that the vast majority of any hits you get are false positives"

**Outcome**: Well-supported. Post-2014 research confirmed that problematic targets (transcription factors, protein-protein interactions) have extremely low true hit rates. Validation cascades became standard, and the false positive problem remained substantial even with PAINS filtering.

• **Prediction**: Academic researchers would continue publishing low-quality PAINS hits without proper validation

**Outcome**: Partially accurate. Publication of PAINS-contaminated results continued through 2015-2018, though awareness gradually increased. By 2020-2022, major journals had implemented stricter chemical validation requirements, reducing but not eliminating the problem.

## 4. INTEREST
Rating: **7/10**

This article addressed a critical quality control issue in drug discovery that had significant practical impact on reducing wasted research effort and improving reproducibility in chemical biology.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20140926-pains-go-mainstream.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_